Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COLL
stocks logo

COLL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
207.07M
+13.81%
2.140
+20.9%
193.96M
+9.12%
1.735
+16.44%
197.24M
+4.91%
1.795
+6.85%
Estimates Revision
The market is revising Upward the revenue expectations for Collegium Pharmaceutical, Inc. (COLL) for FY2025, with the revenue forecasts being adjusted by 3.56% over the past three months. During the same period, the stock price has changed by 23.77%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.09%
In Past 3 Month
Stock Price
Go Up
up Image
+23.77%
In Past 3 Month
Wall Street analysts forecast COLL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 47.33 USD with a low forecast of 46.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast COLL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 47.33 USD with a low forecast of 46.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 47.430
sliders
Low
46.00
Averages
47.33
High
48.00
Current: 47.430
sliders
Low
46.00
Averages
47.33
High
48.00
Truist
Les Sulewski
Buy
maintain
$45 -> $48
2025-11-08
Reason
Truist
Les Sulewski
Price Target
$45 -> $48
2025-11-08
maintain
Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Collegium Pharmaceutical to $48 from $45 and keeps a Buy rating on the shares. The company is reaping rewards from solid back-to-school sales and marketing efforts, which pushed Jornay PM to record revenue, the analyst tells investors in a research note. The outperformance, along with another beat for the pain portfolio, prompted the management to once again raise 2025 guidance across the board, the firm added.
H.C. Wainwright
Brandon Folkes
Buy
maintain
$44 -> $46
2025-11-07
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$44 -> $46
2025-11-07
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Collegium Pharmaceutical to $46 from $44 and keeps a Buy rating on the shares. The company reported a Q3 beat and its cash generation remains underappreciated, the analyst tells investors in a research note.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$44
2025-08-11
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$44
2025-08-11
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Collegium Pharmaceutical with a Buy rating and $44 price target. The firm views the growth potential of Jornay PM as as underappreciated. Jornay has "rapidly emerged as the company's lead growth driver," the analyst tells investors in a research note.
Piper Sandler
Overweight
maintain
$36 -> $37
2025-05-09
Reason
Piper Sandler
Price Target
$36 -> $37
2025-05-09
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Collegium Pharmaceutical to $37 from $36 owing to slightly higher estimates for the legacy pain management business, while keeping an Overweight rating on the shares. The firm notes Collegium reported Q1 adjusted diluted EPS of $1.49 on revenue of $177.8M, compared to consensus of $1.43 and $172.0M, respectively. Guidance for 2025 was unchanged.
Needham
Serge Belanger
Strong Buy
Reiterates
$46
2025-04-09
Reason
Needham
Serge Belanger
Price Target
$46
2025-04-09
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Oren Livnat
Strong Buy
Reiterates
$50
2025-03-24
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
$50
2025-03-24
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Collegium Pharmaceutical Inc (COLL.O) is 6.30, compared to its 5-year average forward P/E of 4.65. For a more detailed relative valuation and DCF analysis to assess Collegium Pharmaceutical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
4.65
Current PE
6.30
Overvalued PE
5.68
Undervalued PE
3.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
3.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.66
Undervalued EV/EBITDA
3.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.60
Current PS
0.00
Overvalued PS
1.99
Undervalued PS
1.20
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

COLL News & Events

Events Timeline

(ET)
2025-11-06
07:39:30
Collegium Pharmaceutical announces Q3 adjusted EPS of $2.25, surpassing consensus estimate of $1.86.
select
2025-10-29 (ET)
2025-10-29
08:11:54
Collegium Pharmaceutical Partners with Paris Hilton
select
2025-08-07 (ET)
2025-08-07
07:43:00
Collegium Pharmaceutical reports Q2 adjusted EPS $1.68, consensus $1.85
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04NASDAQ.COM
Ensign Group Strengthens Presence in Three U.S. States Through Facility Acquisitions

  • Acquisition Details: The Ensign Group, Inc. has acquired four skilled nursing facilities, effective December 1, 2025, increasing its portfolio to 373 healthcare operations across 17 states, including facilities in Colorado, Kansas, and Arizona.

  • Strategic Growth: The acquisitions are part of Ensign's strategy to enhance patient-centered care and strengthen its presence in underserved communities, contributing significantly to its revenue growth, particularly in the Skilled Services segment.

  • Financial Performance: Ensign's shares have increased by 24.4% over the past year, outperforming the industry average, and the company maintains a Zacks Rank #2 (Buy), indicating strong market confidence.

  • Comparative Stock Performance: Other top-ranked stocks in the medical sector, such as Collegium Pharmaceutical, ANI Pharmaceuticals, and Intuitive Surgical, have also shown significant earnings growth and stock performance, with each holding a Zacks Rank #1 (Strong Buy).

[object Object]
Preview
6.5
11-19NASDAQ.COM
Stock of the Day: Collegium Pharmaceutical (COLL)

  • Market Context: Broader valuation concerns in the tech sector and delayed inflation data due to the longest U.S. government shutdown have created market volatility.

  • Collegium Pharmaceutical Overview: Collegium Pharmaceutical (COLL) is a Zacks Rank #1 (Strong Buy) stock focused on pain management drugs with abuse-deterrent formulations, showing strong profitability and growth potential.

  • Financial Performance: Collegium has maintained impressive net income margins, significantly higher than the industry average, and its stock has risen nearly 60% year-to-date, trading at a discount compared to the S&P 500.

  • Future Outlook: The company has raised its full-year revenue guidance and seen positive EPS revisions, indicating strong sales growth and positioning as a defensive hedge amid market uncertainties.

[object Object]
Preview
4.0
11-13NASDAQ.COM
Collegium Pharmaceutical Achieves Analyst Price Target

  • Stock Performance: Collegium Pharmaceutical Inc's shares have surpassed the average analyst 12-month target price of $46.40, currently trading at $47.40/share.

  • Analyst Reactions: Analysts may either downgrade the stock's valuation or raise their target prices in response to the stock reaching the target, depending on the company's fundamental developments.

  • Diverse Analyst Targets: Within the Zacks coverage, analyst targets for COLL vary, with one as low as $44.00 and another as high as $48.00, indicating differing opinions on the stock's future performance.

  • Investor Considerations: Investors are encouraged to evaluate whether the current price of $47.40 is a stepping stone to higher targets or if the valuation has become too stretched, prompting a reassessment of their positions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Collegium Pharmaceutical Inc (COLL) stock price today?

The current price of COLL is 47.43 USD — it has decreased -0.88 % in the last trading day.

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s business?

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

arrow icon

What is the price predicton of COLL Stock?

Wall Street analysts forecast COLL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 47.33 USD with a low forecast of 46.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s revenue for the last quarter?

Collegium Pharmaceutical Inc revenue for the last quarter amounts to 209.36M USD, increased 31.42 % YoY.

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s earnings per share (EPS) for the last quarter?

Collegium Pharmaceutical Inc. EPS for the last quarter amounts to 0.84 USD, increased 211.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Collegium Pharmaceutical Inc (COLL)'s fundamentals?

The market is revising Upward the revenue expectations for Collegium Pharmaceutical, Inc. (COLL) for FY2025, with the revenue forecasts being adjusted by 3.56% over the past three months. During the same period, the stock price has changed by 23.77%.
arrow icon

How many employees does Collegium Pharmaceutical Inc (COLL). have?

Collegium Pharmaceutical Inc (COLL) has 357 emplpoyees as of December 05 2025.

arrow icon

What is Collegium Pharmaceutical Inc (COLL) market cap?

Today COLL has the market capitalization of 1.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free